On the TRAIL of a Solution to Trastuzumab Resistance in HER2+ Breast Cancer

A genomic and proteomic analysis of HER2+ breast cancer cell lines that are resistant to trastuzumab found a deregulation of the cell death pathway known as TRAIL.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news

Related Links:

ConclusionWe confirm previous studies showing that the PTPN2 protein is lost in half of the breast cancer cases and gene deletion occurs in 15 –18% of the cases. Furthermore, the results suggest that the role of PTPN2 is subtype-related and should be further investigated to assess how this could affect breast cancer prognosis and treatment response.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
CONCLUSIONS: Most patients received guideline-concordant AST, except for those with the HR+/HER2+ subtype. Patients receiving guideline-adherent adjuvant therapy had better survival outcomes across all breast cancer subtypes. PMID: 31200362 [PubMed - in process]
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research
This study assessed uptake of the Oncotype DX 21-gene assay over time and characterized which sociodemographic and clinical factors are associated with test uptake among women with lymph node-positive (LN+), hormone receptor-positive, HER2-negative breast cancer. METHODS: Invasive breast cancer cases diagnosed in 2010 through 2013 were included from a SEER database linked to 21-gene assay results performed at Genomic Health's Clinical Laboratory. Factors associated with 21-gene assay uptake were identified using a multivariable logistic regression model. RESULTS: Uptake of the 21-gene assay increased over time and ...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research
AbstractPurposeTo evaluate the efficacy and safety of lapatinib (L) and trastuzumab (T) combination in HER2-positive metastatic breast cancer (MBC) patients previously treated with T and/or L.Materials and methodsWe conducted a retrospective, post-authorized, multicenter study including patients with HER2-positive MBC or locally advanced breast cancer (ABC) treated with the combination of L –T. Concomitant endocrine therapy, as well as brain metastasis and/or prior exposure to L, were allowed.ResultsOne hundred and fifteen patients from 14 institutions were included. The median age was 59.8  years. The median nu...
Source: Clinical and Translational Oncology - Category: Cancer & Oncology Source Type: research
The pattern of locoregional recurrence (LRR) in relation to postoperative locoregional radiotherapy and primary breast cancer biology has been analysed. The 10 year cumulative incidence of LRR was 7.1%. Most LRR developed within the irradiated volume, while the most common location for out-of-field LRR was the cranial supraclavicular fossa. A higher LRR frequency was observed in ER- and/or HER2+ breast cancer. In addition, ER-/Her2+ tumours more frequently recurred in-field (68%) rather than marginal/out-of-field (32%).
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Source Type: research
AbstractPurpose of reviewThis paper will focus on novel breast cancer therapies used in clinical practice today, as well as review our understanding of standard therapies and their potential impact on cardiovascular health.Recent findingsEstablished and novel treatments such as anthracyclines, HER2-targeted agents, and immunotherapy have contributed to improvements in breast cancer outcomes; however, these treatments may be associated with an increased risk of cardiovascular injury. The number of available breast cancer treatments continues to expand, as does the need for health care providers to understand the potential i...
Source: Current Treatment Options in Cardiovascular Medicine - Category: Cardiology Source Type: research
Different conclusions have been drawn from similar findings, perhaps as a result of subjective margins for equivalence in HER2+ breast cancer research.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Authors: Exman P, Pernas S, Tolaney SM PMID: 31188804 [PubMed - in process]
Source: Clinical Advances in Hematology and Oncology - Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research
A phase II trial tested docetaxel, trastuzumab, and pertuzumab vs T-DM1 for the neoadjuvant treatment of HER2+ breast cancer.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
Approval Based on Totality of Evidence Demonstrating KANJINTI is Biosimilar to Herceptin Third FDA Approval From Amgen's Biosimilars Portfolio THOUSAND OAKS, Calif., June 13, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) today announced that the U.S. Food and Drug Administration (FDA) has approved KANJINTI™ (trastuzumab-anns) for all approved indications of the reference product, Herceptin® (trastuzumab):  for the treatment of HER2-overexpressing adjuvant and metastatic breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. "...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | HER2 | Herceptin